Aspire BioPharma, Inc. (ASBP) — Financial Flexibility Index
Aspire BioPharma, Inc. (ASBP) has a Financial Flexibility Index of -0.94x as of March 2026. Free cash flow of $-3.04 Million (operating CF $-3.04 Million minus capex $0.00) represents -1% of total liabilities ($3.25 Million). Check total reinvestment intensity of Aspire BioPharma, Inc. to assess the company's total reinvestment commitment from operating cash flow.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Aspire BioPharma, Inc. Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Aspire BioPharma, Inc. across 5 annual periods. For the full cash flow conversion analysis, see Aspire BioPharma, Inc. (ASBP) cash conversion ratio.
Annual Financial Flexibility Index for Aspire BioPharma, Inc. (2021–2025)
Year-by-year free cash flow to debt coverage for Aspire BioPharma, Inc.. Explore debt repayment capacity of Aspire BioPharma, Inc. to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.64x | $-4.92 Million | $-4.92 Million | $7.69 Million | ▼ -307.6% |
| 2024 | -0.16x | $-265.19K | $-265.19K | $1.69 Million | ▲ +90.3% |
| 2023 | -1.62x | $-653.10K | $-653.11K | $403.33K | ▼ -1177.7% |
| 2022 | -0.13x | $-1.41 Million | $-1.41 Million | $11.12 Million | ▼ -14216.2% |
| 2021 | 0.00x | $-260.00 | $-260.00 | $293.70K | — |